Comment on

• Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

  Ravdin PM, Burris HA 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE. Ravdin PM, et al. J Clin Oncol. 1995 Dec;13(12):2879-85. doi: 10.1200/JCO.1995.13.12.2879. J Clin Oncol. 1995. PMID: 8523050 Clinical Trial.
• Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

  Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN. Valero V, et al. J Clin Oncol. 1995 Dec;13(12):2886-94. doi: 10.1200/JCO.1995.13.12.2886. J Clin Oncol. 1995. PMID: 8523051 Clinical Trial.
• Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.

  Bedikian AY, Weiss GR, Legha SS, Burris HA 3rd, Eckardt JR, Jenkins J, Eton O, Buzaid AC, Smetzer L, Von Hoff DD, et al. Bedikian AY, et al. J Clin Oncol. 1995 Dec;13(12):2895-9. doi: 10.1200/JCO.1995.13.12.2895. J Clin Oncol. 1995. PMID: 8523052 Clinical Trial.